Xie Li-Hua, Akao Teruaki, Hamasaki Kenjiro, Deyama Takeshi, Hattori Masao
Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Sugitani, Toyama, Japan.
Chem Pharm Bull (Tokyo). 2003 May;51(5):508-15. doi: 10.1248/cpb.51.508.
By anaerobic incubation of pinoresinol diglucoside (1) from the bark of Eucommia ulmoides with a fecal suspension of humans, eleven metabolites were formed, and their structures were identified as (+)-pinoresinol (2), (+)-lariciresinol (3), 3'-demethyl-(+)-lariciresinol (4), (-)-secoisolariciresinol (5), (-)-3-(3", 4"-dihydroxybenzyl)-2-(4'-hydroxy-3'-methoxybenzyl)butane-1, 4-diol (6), 2-(3', 4'-dihydroxybenzyl)-3-(3", 4"-dihydroxybenzyl)butane-1, 4-diol (7), 3-(3"-hydroxybenzyl)-2-(4'-hydroxy-3'-methoxybenzyl)butane-1, 4-diol (8), 2-(3', 4'-dihydroxybenzyl)-3-(3"-hydroxybenzyl)butane-1, 4-diol (9), (-)-enterodiol (10), (-)-(2R, 3R)-3-(3", 4"-dihydroxybenzyl)-2-(4'-hydroxy-3'-methoxybenzyl)butyrolactone (11), (-)-(2R, 3R)-2-(3', 4'-dihydroxybenzyl)-3-(3", 4"-dihydroxybenzyl)butyrolactone (12), (-)-(2R, 3R)-3-(3"-hydroxybenzyl)-2-(4'-hydroxy-3'-methoxybenzyl)butyrolactone (13), 2-(3', 4'-dihydroxybenzyl)-3-(3"-hydroxybenzyl)butyrolactone (14), 2-(3'-hydroxybenzyl)-3-(3", 4"-dihydroxybenzyl)butyrolactone (15) and (-)-(2R, 3R)-enterolactone (16) by various spectroscopic means, including two dimensional (2D)-NMR, mass spectrometry and circular dichroism. A possible metabolic pathway was proposed on the basis of their structures and time course experiments monitored by thin-layer chromatography. Furthermore, a bacterial strain responsible for the transformation of (+)-pinoresinol to (+)-lariciresinol was isolated from a human fecal suspension and identified as Enterococcus faecalis strain PDG-1.
通过将杜仲树皮中的松脂醇二葡萄糖苷(1)与人粪便悬浮液进行厌氧培养,形成了11种代谢产物,通过包括二维(2D)-NMR、质谱和圆二色性在内的各种光谱手段鉴定出它们的结构分别为(+)-松脂醇(2)、(+)-落叶松脂醇(3)、3'-去甲基-(+)-落叶松脂醇(4)、(-)-开环异落叶松脂醇(5)、(-)-3-(3",4"-二羟基苄基)-2-(4'-羟基-3'-甲氧基苄基)丁烷-1,4-二醇(6)、2-(3',4'-二羟基苄基)-3-(3",4"-二羟基苄基)丁烷-1,4-二醇(7)、3-(3"-羟基苄基)-2-(4'-羟基-3'-甲氧基苄基)丁烷-1,4-二醇(8)、2-(3',4'-二羟基苄基)-3-(3"-羟基苄基)丁烷-1,4-二醇(9)、(-)-肠二醇(10)、(-)-(2R,3R)-3-(3",4"-二羟基苄基)-2-(4'-羟基-3'-甲氧基苄基)丁内酯(11)、(-)-(2R,3R)-2-(3',4'-二羟基苄基)-3-(3",4"-二羟基苄基)丁内酯(12)、(-)-(2R,3R)-3-(3"-羟基苄基)-2-(4'-羟基-3'-甲氧基苄基)丁内酯(13)、2-(3',4'-二羟基苄基)-3-(3"-羟基苄基)丁内酯(14)、2-(3'-羟基苄基)-3-(3",4"-二羟基苄基)丁内酯(15)和(-)-(2R,3R)-肠内酯(16)。基于它们的结构和通过薄层色谱监测的时间进程实验,提出了一条可能的代谢途径。此外,从人粪便悬浮液中分离出一株负责将(+)-松脂醇转化为(+)-落叶松脂醇的细菌菌株,并鉴定为粪肠球菌菌株PDG-1。